Oral Contraceptive Use and BRCA Penetrance: A Case-Only Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] Journal article | | Title | Oral Contraceptive Use and BRCA Penetrance: A Case-Only Study. | | Author(s) | Pasanisi P, Hédelin G, Berrino J, Chang-Claude J, Hermann S, Steel M, Haites N, Hart J, Peled R, Gafà L, Leggio L, Traina A, Amodio R, Primic-Zakelj M, Zadnik V, Veidebaum T, Tekkel M, Berrino F | | Institution | Department of Preventive and Predictive Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy; Department of Epidemiology, Faculty of Medicine of the University of Strasbourg, Strasbourg, France; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Bute Medical School, University of St Andrews, St Andrews, Scotland; Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland; Loewenstein Rehabilitation Hospital Raanana, Israel Sacler School of Medicine, University of Tel Aviv, Tel Aviv, Israel; Department of Systems Management, Faculty of Health Science, Ben Gurion University of the Negev, BeerSheva, Israel; Italian League Against Cancer, Ragusa Section, Ragusa, Italy; Department of Oncology, Palermo Breast Cancer Registry, Ospedale Civico "M. Ascoli," Palermo, Italy; Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia; and Departments of Oncology and Immunology, Estonia and Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia. | | Source | Cancer Epidemiol Biomarkers Prev 2009 Jun 23. | | Abstract | BACKGROUND: Women with deleterious mutations in BRCA genes are at increased risk of breast cancer. However, the penetrance of the genetic trait may be regulated through environmental factors. This multinational case-only study tested the interaction between oral contraceptive use and genetic susceptibility in the occurrence of breast cancer.
METHODS: We recruited 3,123 patients diagnosed with breast cancer before the age of 45 years. Participants were classified according to their probability of carrying a BRCA mutation on the basis of their family history of breast and ovarian cancer. According to a case-only approach, the frequency of relevant exposures among breast cancer cases with high probability of BRCA mutation ("genetic cases") was compared with the frequency of the same exposures among breast cancer cases with a low probability of BRCA mutation ("sporadic cases"). The interaction odds ratios (OR) and 95% confidence intervals (CI) for oral contraceptive use were estimated by unconditional logistic regression, after controlling for potentially confounding variables.
RESULTS: The analysis was carried out comparing 382 "genetic" and 1,333 "sporadic" cases. We found a borderline significant interaction between genetic breast cancer and oral contraceptive use for ever users compared with never users (OR, 1.3; 95% CI, 1.0-1.7). The greatest interaction OR was found for women who started using pill at 18 to 20 years (OR, 1.6; 95% CI, 1.1-2.3).
CONCLUSION: These results suggest that BRCA mutation carriers, as well as women with a significant family history of breast and ovarian cancer are more vulnerable to exogenous hormones in oral contraceptives. (Cancer Epidemiol Biomarkers Prev 2009;18(7):2107-13). | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19549808 |
|
|
| |
Advertise on this site.
| | |
|
